Eye-drop is the most common dosage for ophthalmic delivery, but only 5 % of the administered dose retained in the eye after 5 min. The role of the ophthalmology care is focused on raising drug bioavailability in ocular tissue. In order to develop an effective vehicle for ophthalmic application, polymeric nanoparticles are chosen as new ophthalmic carriers. Dry eye disease (DED) is a general disease in ophthalmic clinic causing by ocular surface inflammation. About 15 % of adult suffer from this problem. Epigallocatechin gallate (EGCG), the major kind of tea polyphenols, is adopted for DED treatment due to its anti-inflammation effect. Biopolymer, gelatin, with superior biocompatibility can be used as the vehicle for ocular drug delivery. With hyaluronic acid (HA) combination, interaction of nanocarriers and cornea could be increased by mucus adhesive improvement. In the present study, we are going to develop HA modified gelatin nanoparticles (HA-GPs) loaded with EGCG (HA-GPs-EGCG) for the management of DED. The developed nanocarriers could be characterized by examination such as zeta potential, particle size, entrapment efficiency, and in vitro release in PBS. Biocompatibility and anti-inflammation effect could be checked in vitro by corneal epithelium cells. Topical EGCG administration may have more effective therapeutic outcome for DED treatment. A DED rabbit model could be established in this study and rabbits will received eye drops with HA-GPs-EGCG to examine the therapy effect. Based on these considerations, a HA-GPs nanocarriers system with drug encapsulation could be developed; it may have the potential to deliver variant kinds of drug for different ocular disease treatment in the future.
|Effective start/end date||8/1/12 → 7/31/13|
- tea polyphenols
- dry eye disease
- drug delivery
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.